Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib

Clinical Science

Volumn 128, Issue 1, 2015, Pages 29-37

  Peveling Oberhag, Jan ^a   Do¨ring, Claudia ^a   Hartmann, Sylvia ^a   Filmann, Natalie ^b   Mertens, Angelika ^a   Piiper, Albrecht ^a   Herrmann, Eva ^b   Hansmann, Martin Leo ^a   Zeuzem, Stefan ^a   Trojan, Jo¨rg ^a   Welker, Martin Walter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Cancer; Hepatocellular carcinoma (HCC); Liver; miRNA; Sorafenib

Indexed keywords

FORMALDEHYDE; MICRORNA; PARAFFIN; RNA; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; GENETIC MARKER; NICOTINAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE CONTROL; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DNA MICROARRAY; DRUG EFFECTS; FEASIBILITY STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RETROGNATHIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NIACINAMIDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENYLUREA COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; RETROGNATHIA; TREATMENT OUTCOME;

EID: 84907222945     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20140007     Document Type: Article

References (63)

1. Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108
2. Cabibbo, G., Enea, M., Attanasio, M., Bruix, J., Craxi, A. and Camma, C. (2010) A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51, 1274-1283
3. Llovet, J. M., Burroughs, A. and Bruix, J. (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917
4. El Serag, H. B. and Rudolph, K. L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576
5. El Serag, H. B. and Mason, A. C. (1999) Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745-750
6. Taura, N., Yatsuhashi, H., Hamasaki, K., Nakao, K., Daikoku, M., Ueki, T., Yano, K., Matsumoto, T., Ishibashi, H. and Eguchi, K. (2006) Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: long term trends in Japan. Hepatol. Res. 34, 130-134
7. Ekstedt, M., Franzen, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G. and Kechagias, S. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873
8. Fattovich, G., Stroffolini, T., Zagni, I. and Donato, F. (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127, S35-S50
9. Llovet, J. M., Bru, C. and Bruix, J. (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329-338
10. Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Sole, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M. et al. (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47, 97-104
11. Bruix, J. and Sherman, M. (2011) Management of hepatocellular carcinoma: an update. Hepatology 53, 1020-1022
12. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R. and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844
13. Welker, M. W. and Trojan, J. (2011) Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. World J. Gastroenterol. 17, 3075-3081
14. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A. et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390
15. Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T. S. et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34
16. Abbadessa, G., Rimassa, L., Pressiani, T., Carrillo-Infante, C., Cucchi, E. and Santoro, A. (2011) Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J. Gastroenterol. 17, 2450-2453
17. Gerardi, A. M., Stoppino, L. P., Liso, A., Macarini, L. and Landriscina, M. (2013) Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. Oncol. Lett. 5, 975-977
18. Worns, M. A., Weinmann, A., Pfingst, K., Schulte-Sasse, C., Messow, C. M., Schulze-Bergkamen, H., Teufel, A., Schuchmann, M., Kanzler, S., Duber, C. et al. (2009) Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 43, 489-495
19. Welker, M. W., Lubomierski, N., Gog, C., Herrmann, E., Engels, K., Vogl, T., Bechstein, W., Zeuzem, S. and Trojan, J. (2010) Use of sorafenib in advanced hepatocellular carcinoma-a case study of a German Liver Center. Onkologie 33, 86-86
20. Personeni, N., Bozzarelli, S., Pressiani, T., Rimassa, L., Tronconi, M. C., Sclafani, F., Carnaghi, C., Pedicini, V., Giordano, L. and Santoro, A. (2012) Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 57, 101-107
21. Nana-Sinkam, S. P. and Croce, C. M. (2010) MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. IDrugs 13, 843-846
22. Sotiropoulou, G., Pampalakis, G., Lianidou, E. and Mourelatos, Z. (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15, 1443-1461
23. Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y. et al. (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140, 1618-1628
24. Goldberg, S. N., Charboneau, J. W., Dodd, III, G. D., Dupuy, D. E., Gervais, D. A., Gillams, A. R., Kane, R. A., Lee, Jr, F. T., Livraghi, T., McGahan, J. P. et al. (2003) Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 228, 335-345
25. Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H. and Kanehisa, M. (1999) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 27, 29-34
26. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.R. Statist. Soc. B 57, 289-300
27. Vlachos, I. S., Kostoulas, N., Vergoulis, T., Georgakilas, G., Reczko, M., Maragkakis, M., Paraskevopoulou, M. D., Prionidis, K., Dalamagas, T. and Hatzigeorgiou, A. G. (2012) DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 40, W498-W504
28. Villanueva, A., Hoshida, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., Cornella, H., Liberzon, A., Kobayashi, M., Kumada, H. et al. (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140, 1501-1512
29. Zucnan-Rossi, J. and Laurent-Puig, P. (2007) Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics 8, 997-1003
30. Ambros, V. (2004) The functions of animal microRNAs. Nature 431, 350-355
31. Wong, C. C., Wong, C. M., Tung, E. K., Au, S. L., Lee, J. M., Poon, R. T., Man, K. and Ng, I. O. (2011) The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 140, 322-331
32. Xiong, Y., Fang, J. H., Yun, J. P., Yang, J., Zhang, Y., Jia, W. H. and Zhuang, S. M. (2010) Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51, 836-845
33. Wei, R., Huang, G. L., Zhang, M. Y., Li, B. K., Zhang, H. Z., Shi, M., Chen, X. Q., Huang, L., Zhou, Q. M., Jia, W. H. et al. (2013) Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin. Cancer Res. 19, 4780-4791
34. Xia, H., Ooi, L. L. and Hui, K. M. (2013) MicroRNA-216a/217- induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58, 629-641
35. Zhu, K., Pan, Q., Zhang, X., Kong, L. Q., Fan, J., Dai, Z., Wang, L., Yang, X. R., Hu, J., Wan, J. L. et al. (2013) MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis 34, 2071-2079
36. Hou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q., Qin, L., Wu, X., Zheng, Y., Yang, Y. et al. (2011) Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232-243
37. Jiang, J., Gusev, Y., Aderca, I., Mettler, T. A., Nagorney, D. M., Brackett, D. J., Roberts, L. R. and Schmittgen, T. D. (2008) Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 14, 419-427
38. Connolly, E., Melegari, M., Landgraf, P., Tchaikovskaya, T., Tennant, B. C., Slagle, B. L., Rogler, L. E., Zavolan, M., Tuschl, T. and Rogler, C. E. (2008) Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol. 173, 856-864
39. Gramantieri, L., Ferracin, M., Fornari, F., Veronese, A., Sabbioni, S., Liu, C. G., Calin, G. A., Giovannini, C., Ferrazzi, E., Grazi, G. L. et al. (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67, 6092-6099
40. Huang, X. H., Wang, Q., Chen, J. S., Fu, X. H., Chen, X. L., Chen, L. Z., Li, W., Bi, J., Zhang, L. J., Fu, Q. et al. (2009) Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol. Res. 39, 786-794
41. Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M. and Rodes, J. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430
42. Murakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanoue, T. and Shimotohno, K. (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537-2545
43. Doleshal, M., Magotra, A. A., Choudhury, B., Cannon, B. D., Labourier, E. and Szafranska, A. E. (2008) Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 10, 203-211
44. Liu, A. and Xu, X. (2011) MicroRNA isolation from formalin-fixed, paraffin-embedded tissues. Methods Mol. Biol. 724, 259-267
45. Zhang, X., Chen, C., Wu, M., Chen, L., Zhang, J., Zhang, X., Zhang, Z., Wu, J., Wang, J., Chen, X. et al. (2012) Plasma microRNA profile as a predictor of early virological response to interferon treatment in chronic hepatitis B patients. Antivir. Ther. 17, 1243-1253
46. Gramantieri, L., Ferracin, M., Fornari, F., Veronese, A., Sabbioni, S., Liu, C. G., Calin, G. A., Giovannini, C., Ferrazzi, E., Grazi, G. L. et al. (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67, 6092-6099
47. Lan, F. F., Wang, H., Chen, Y. C., Chan, C. Y., Ng, S. S., Li, K., Xie, D., He, M. L., Lin, M. C. and Kung, H. F. (2011) Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Int. J. Cancer 128, 319-331
48. Felli, N., Felicetti, F., Lustri, A. M., Errico, M. C., Bottero, L., Cannistraci, A., De Feo, A., Petrini, M., Pedini, F., Biffoni, M. et al. (2013) miR-126&126.*restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PloS One 8, e56824
49. Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., Chang, T. C., Vivekanandan, P., Torbenson, M., Clark, K. R. et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017
50. Braconi, C., Kogure, T., Valeri, N., Huang, N., Nuovo, G., Costinean, S., Negrini, M., Miotto, E., Croce, C. M. and Patel, T. (2011) microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30, 4750-4756
51. Li, D., Liu, X., Lin, L., Hou, J., Li, N., Wang, C., Wang, P., Zhang, Q., Zhang, P., Zhou, W. et al. (2011) MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J. Biol. Chem. 286, 36677-36685
52. Petrelli, A., Perra, A., Schernhuber, K., Cargnelutti, M., Salvi, A., Migliore, C., Ghiso, E., Benetti, A., Barlati, S., Ledda-Columbano, G. M. et al. (2012) Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 31, 4517-4526
53. Bissell, D. M., Roulot, D. and George, J. (2001) Transforming growth factor beta and the liver. Hepatology 34, 859-867
54. Breuhahn, K., Longerich, T. and Schirmacher, P. (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25, 3787-3800
55. Grabinski, N., Ewald, F., Hofmann, B. T., Staufer, K., Schumacher, U., Nashan, B. and Jucker, M. (2012) Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol. Cancer 11, 85
56. Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M., Higashiyama, S., Noda, K., Miyoshi, E., Monden, M. and Matsuura, N. (2001) Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 84, 1377-1383
57. Vivanco, I. and Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501
58. Lim, L., Balakrishnan, A., Huskey, N., Jones, K. D., Jodari, M., Ng, R., Song, G., Riordan, J., Anderton, B., Cheung, S. T. et al. (2014) MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 59, 202-215
59. Chung, G. E., Yoon, J. H., Myung, S. J., Lee, J. H., Lee, S. H., Lee, S. M., Kim, S. J., Hwang, S. Y., Lee, H. S. and Kim, C. Y. (2010) High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol. Rep. 23, 113-119
60. Huang, Y. H., Lin, K. H., Chen, H. C., Chang, M. L., Hsu, C. W., Lai, M. W., Chen, T. C., Lee, W. C., Tseng, Y. H. and Yeh, C. T. (2012) Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One 7, e37188
61. Henry, J. C., Park, J. K., Jiang, J., Kim, J. H., Nagorney, D. M., Roberts, L. R., Banerjee, S. and Schmittgen, T. D. (2010) miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun. 403, 120-125
62. Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G. A., Grazi, G. L., Pollutri, D., Croce, C. M., Bolondi, L. and Gramantieri, L. (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70, 5184-5193
63. Wang, C., Song, B., Song, W., Liu, J., Sun, A., Wu, D., Yu, H., Lian, J., Chen, L. and Han, J. (2011) Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J. Gastroenterol. Hepatol. 26, 1630-1637